Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries.
Rifamycin SV MMX®is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers’ Diarrhea caused by certain bacteria. It works by stopping the growth of the bacteria that cause diarrhea. It is the first antibiotic engineered with Cosmo’s proprietary Multi Matrix Technology (MMX®). MMX technology is designed to deliver the active pharmaceutical ingredients in a delayed and controlled manner directly to the lower intestine.
About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline. For additional information on Cosmo and its products, please visit www.cosmopharma.com.
Upcoming Calendar of Events
Investor Access, Paris October 9-10, 2023
Jefferies London Healthcare Conference 2023 November 14-16, 2023
CF&B Communication European Midcap Event, Geneva December 1-2, 2023
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Contact:
Hazel Winchester, Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70